Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,...
Reexamination Certificate
2007-10-29
2010-10-26
Huynh, Phuong (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
C424S146100, C424S178100, C514S235500, C514S414000, C544S121000, C544S283000
Reexamination Certificate
active
07820159
ABSTRACT:
The invention is based upon the discovery that the EGFR pathway can stimulate a previously unknown tumorigenic function of CA IX, via phosphorylation of the sole tyrosine residue present in CA IX's intracellular domain. EGFR-phosphorylated CA IX then interacts with the p85 subunit of PI3K to activate Akt, which in turn is associated with anti-apototic function and increased cell survival. The latter finding indicates that there is a positive feedback loop for CA9 expression mediated by the PI3K pathway in preneoplastic
eoplastic diseases. Disclosed herein are novel therapeutic methods for treating preneoplastic
eoplastic diseases associated with abnormal MN/CA IX expression, using EGFR pathway inhibitors. Preferably, the EGFR pathway inhibitors are tyrosine kinase inhibitors or EGFR-specific antibodies. Further disclosed are methods for patient therapy selection for EGFR pathway inhibitors, preferably in combination with other cancer therapies, based on detection of abnormal MN/CA9 gene expression in preneoplastic
eoplastic tissues.
REFERENCES:
patent: 5387676 (1995-02-01), Zavada et al.
patent: 6297041 (2001-10-01), Zavada et al.
patent: 6548496 (2003-04-01), Wissner et al.
patent: 6864286 (2005-03-01), Uckun et al.
patent: 7115715 (2006-10-01), Zavada et al.
patent: 7378091 (2008-05-01), Gudas et al.
patent: 7384940 (2008-06-01), Agus
patent: 2005/0031623 (2005-02-01), Pastorek et al.
patent: 2008/0038251 (2008-02-01), Pastorekova et al.
patent: WO 93/18152 (1993-09-01), None
patent: WO 95/34650 (1995-12-01), None
patent: WO 96/40210 (1996-12-01), None
patent: WO 00/24913 (2000-05-01), None
patent: WO 03/100029 (2003-12-01), None
Wong et al, Clinical Therapeutics 27(6): 684-694, 2005.
Stadler et al, Cancer 104: 2323-2333, Dec. 2005.
Staehler et al, Current Drug Targets 6(7): 835-846, Nov. 2005.
Giaccone et al, Annals of Oncology 16: 538-548, 2005.
Verma et al, Nature 389: 239-242, Sep. 1997.
Harari et al, Endocrine-Related Cancer 11: 689-708, Dec. 2004.
Wilhelm et al, Cancer Res 64: 7099-7109, Oct. 2004.
Klire et al, Bioorganic & Medicinal Chemistry Letter 14: 783-786, Feb. 2004.
Post et al, Clinical Cancer Research 10: 8603-8612, Dec. 2004.
Uemura et al, British J Cancer 81(4): 741-746, Oct. 1999.
Mendelsohn et al, J Clinical Oncology 21(14): 2787-2799, Jul. 2003.
Kopacek et al, Biochimica et Biophysica Acta 1729: 41-49, 2005, abstract only.
Stadler et al, Current Drug Targets 6(7): 835-846, 2005.
Rubyani et al, Molecular Aspects of Medicine 22: 113-142, 2001.
Stancoviski et al, Proceedings of the National Academy of Science USA 88: 8691-8695, 1991.
Riemer et al, Mol. Immunol. 42: 1121-1124, 2005.
Cochran et al, J. Immunol. Meth. 287: 147-158, 2004.
Bardos and Ashcroft, “Hypoxia-inducible factor-1 and oncogenic signalling,”BioEssays, 26.3: 262-269 (2004).
Chia et al., “Prognositc Significance of a Novel Hypoxia-Regulated Marker, Carbonic Anhydrase IX, in Invasive Breast Carcinoma,”Journal of Clinical Oncology, 19(16): 3660-3668 (Aug. 15, 2001).
Christina et al., “Biodistribution and Pharmacokinetics of 125I-Labeled Monoclonal Antibody M75 Specific for Carbonic Anhydrase IX, an Intrinsic Marker of Hypoxia, in Nude Mice Xenografted with Human Colorectal Carcinoma,”Int. J. Cancer: 105: 873-881 (2003).
Dorai et al., “The role of carbonic anhydrase IX overexpression in kidney cancer,”European Journal of Cancer, 41: 2935-2947 (2005).
Dorai et al., “Role of Carbonic Anhydrases in the Progression of Renal Cell Carcinoma Subtypes: Proposal of a Unified Hypothesis,”Cancer Investigation, 24: 754-779 (2006).
Giatromanolaki et al., “Expression of Hypoxia-inducible Carbonic Anhydrase-9 Relates to Angiogenic Pathways and Independently to Poor Outcome in Non-Small Cell Lung Cancer,”Cancer Research, 61: 7992-7998 (Nov. 1, 2001).
Goethals et al., “Hypoxia in Human Colorectal Adenocarcinoma: Comparison Between Extrinsic and Potential Intrinsic Hypoxia Markers,”Int. J. Radiation Oncology Biol. Phys., 65(1): 246-254 (2006).
Gollob, J.A., “Sorafenib: Scientific Rationales for Single-Agent and Combination Therapy in Clear-Cell Renal Cell Carcinoma,”Clinical Genitourinary Cancer, 4(3): 167-174 (2005).
Gollob et al., “Role of Raf Kinase in Cancer: Therapeutic Potential of Targeting the Raf/MEK/ERK Signal Transduction Pathway,”Seminars in Oncology, 33(4): 392-406 (2006).
Haddad, J.J., “Hypoxia and the regulation of mitogen-activated protein kinases: gene transcription and the assessment of potential pharmacologic therapeutic interventions,”International Immunopharmacology, 4: 1249-1285 (2004).
Harris, A.L., “Hypoxia—A Key Regulatory Factor in Tumour Growth,”Nature Reviews, 2: 38-47 (Jan. 2002).
Ihnatko et al., “Extracellular acidosis elevates carbonic anhydrase IX in human glioblastoma cells via transcriptional modulation that does not depend on hypoxia,”International Journal of Oncology, 29: 1025-1033 (2006).
Ivanov et al., “Expression of Hypoxia-Inducible Cell-Surface Transmembrane Carbonic Anhydrases in Human Cancer,”American Journal of Pathology, 158(3): 905-919 (Mar. 2001).
Kaluz et al., “Lowered Oxygen Tension Induces Expression of the Hypoxia Marker MN/Carbonic Anhydrase IX in the Absence of Hypoxia-inducible Factor 1alpha Stabilization: A Role for Phosphatidylinositol 3′-Kinase,”Cancer Research, 62: 4469-4477 (Aug. 1, 2002).
Kopacek et al., “MAPK pathway contributes to density- and hypoxia-induced expression of the tumor-associated carbonic anhydrase IX,”Biochimica et Biophysica Acta, 1729: 41-49 (2005).
Lam et al., “Renal Cell Carcinoma 2005: New Frontiers in Staging, Prognostication and Targeted Molecular Therapy,”Journal of Urology, 173: 1853-1862 (Jun. 2005).
Lam et al., “Novel approaches in the therapy of metastatic renal cell carcinoma,”World J. Urol., 23: 202-212 (2005).
Liao et al., “Identification of the MN/CA9 Protein As a Reliable Diagnostic Biomarker of Clear Cell Carcinoma of the Kidney,”Cancer Research, 57: 2827-2831 (Jul. 15, 1997).
Marshall, J., “Clinical Implications of the Mechanism of Epidermal Growth Factor Receptor Inhibitors,”Cancer, 107(6): 1207-1218 (Sep. 15, 2006).
McKiernan et al., “Expression of the Tumor-associated GeneMN: A Potential Biomarker for Human Renal Cell Carcinoma,”Cancer Research, 57: 2362-2365 (Jun. 15, 1997).
Opavsky et al., “HumanMN/CA9Gene, a Novel Member of the Carbonic Anhydrase Family: Structure and Exon to Protein Domain Relationships,”Genomics, 33: 480-487 (1996).
Pastorek et al., “Cloning and characterization of MN, a human tumor-associated protein with a domain homologous to carbonic anhydrase and a putative helix-loop-helix DNA binding segment,”Oncogene, 9: 2877-2888 (1994).
Pastorekova and Pastorek, “MN/CA IX and MAPK Inhibition,” U.S. Appl. No. 11/726,065, filed Mar. 20, 2007).
Pastorekova and Zavada, “Carbonic anhydrase IX (CA IX) as a potential target for cancer thereapy,”Cancer Therapy, 2: 245-262 (2004).
Patard et al., “Understanding the Importance of Smart Drugs in Renal Cell Carcinoma,”European Urology, 49: 633-643 (2006).
Robertson et al., “Role of Carbonic Anhydrase IX in Human Tumor Cell Growth, Survival, and Invasion,”Cancer Research, 64: 6160-6165 (Sep. 1, 2004).
Said, J., “Biomarker discovery in urogenital cancer,”Biomarkers, 10(Supp. 1): S83-S86 (Nov. 2005).
Sorenson et al., “Influence of oxygen concentration and pH on expression of hypoxia induced genes,”Radiotherapy and Oncology, 76: 187-193 (2005).
Svastova et al., “Carbonic anhydrase IX reduces E-cadherin-mediated adhesion of MDCK cells via interaction with beta-catenin,”Experimental Cell Research, 290: 332-345 (2003).
Svastova et al., “Hypoxia activates the capacity of tumor-associated carbonic anhydrase IX to acidify extracellular pH,”
Harland Joan C.
Huynh Phuong
Instiute of Virology of the Slovak Academy of Sciences
Lauder Leona L.
Shimei Barbara A.
LandOfFree
MN/CA IX and EGFR pathway inhibition does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with MN/CA IX and EGFR pathway inhibition, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and MN/CA IX and EGFR pathway inhibition will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4179683